Perceptive Discovery Appoints Dr. Benjamin Bronfin as Vice President of Operations

Perceptive Discovery appointed Benjamin Bronfin, MD, as Vice President of Operations, the company said in a PR Newswire announcement dated November 10, 2026. Dr. Bronfin brings more than 25 years of leadership experience across contract research organizations, biotechnology, pharmaceutical development and laboratory operations.

Bronfin's Role at Perceptive Discovery

In the role, Dr. Bronfin will lead efforts to strengthen operational efficiency, enhance service delivery and build scalable infrastructure supporting growth across oncology and radioligand therapy drug development. He will focus on strengthening operational processes, improving cross-functional coordination and driving execution of key initiatives.

Prior to joining Perceptive Discovery, Dr. Bronfin held senior positions at Pharmaron Laboratory Services and Cambridge Biomedical, where he led scientific operations, expanded service capabilities and drove organizational growth. He holds a Doctor of Medicine degree from Omsk State Medical Academy.

"Benjamin brings a strong combination of scientific expertise, operational leadership, and a proven ability to build and scale high-performing organizations," said Benjamin Murphy, Chief Executive Officer of Perceptive.

"I'm excited to join Perceptive Discovery at such an important stage in its growth," said Dr. Bronfin. "The organization has exceptional scientific expertise and a strong foundation in preclinical and translational research."

Perceptive's Recent Expansion Moves

According to akta.pro company records, Perceptive Discovery expanded its Needham, MA in vitro lab capabilities in April 2026 with a five-fold increase in tissue culture space to accelerate preclinical oncology research capacity. The same records show a January 2026 private equity round of $15 million led by CapVest.

Radiopharmaceutical Work Before the Appointment

In October 2026, Perceptive Discovery announced availability of astatine-211 radiopharmaceutical development studies at its US and UK locations, becoming the first US provider to execute such studies, PR Newswire reported. Earlier that month, Perceptive Discovery and Nucleus RadioPharma announced a strategic partnership to accelerate radiopharmaceutical development from preclinical imaging to clinical manufacturing, according to PR Newswire.